Oppenheimer analyst Francois Brisebois reiterates his Outperform rating and $63 price target on MediWound after the FDA announced approval of NexoBrid for the treatment of severe burns "slightly earlier" than the PDUFA target date of January 1. He is "further encouraged" that the FDA approval should trigger a $7.5M milestone payment and looks forward to updates on the upcoming pivotal EscharEx Phase 3 trial for the debridement of VLUs expected to start in the first half of 2023, Brisebois tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDWD:
- MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
- MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
- MediWound announces marketing approval of NexoBrid in Japan
- Biotech Alert: Searches spiking for these stocks today
- MediWound initiated with a Buy at Maxim